...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of hyperthermia: The official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group >Ultrasound-guided percutaneous microwave ablation assisted by athree-dimensional visualization treatment platform combined with transcatheter arterial chemoembolization for a single large hepatocellular carcinoma 5?cm or larger: a preliminary clinical application
【24h】

Ultrasound-guided percutaneous microwave ablation assisted by athree-dimensional visualization treatment platform combined with transcatheter arterial chemoembolization for a single large hepatocellular carcinoma 5?cm or larger: a preliminary clinical application

机译：超声引导下经皮微波消融结合三维可视化治疗平台结合经导管动脉化疗栓塞治疗单个5厘米或更大的大型肝细胞癌：初步临床应用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To assess the clinical efficiency and feasibility of ultrasound-guided percutaneous microwave ablation (US-PMWA) assisted by a three-dimensional (3D) visualization platform for treating a single large hepatocellular carcinoma (HCC) (diameter ≥5?cm). We included 40 patients with a single large HCC from May 2015 to August 2017. Nineteen patients who underwent US-PMWA assisted by a 3D visualization platform formed the 3D group; 21 patients without 3D visualization assistance formed the control group. Preoperative planning and post-procedural evaluation were performed successfully with the 3D visualization treatment platform. Thermal ablative parameters, survival and recurrence were compared between groups. The primary efficacy rate and recurrence-free survival (RFS) rate in the 3D group were higher than those in the control group (p?=?.007 and p?=?.014, respectively). The number of inserted probes in the 3D group was higher than that in the control group (p?=?.016). The overall survival (OS) rate in the 3D group was comparable to that of controls (p?=?.745). Estimated 3-year OS and RFS rates were 38.5% and 64.6% in the 3D group and 34.4% and 18.8% in the control group, respectively. Treatment effects were evaluated using a tumor map and confirmed by traditional contrast-enhanced ultrasound in the 3D group. After the first treatment, nine patients (47.4%) achieved complete ablation with a 5-mm safety margin. No major complications related to ablation occurred. US-PMWA assisted by a 3D visualization treatment platform can improve treatment efficiency and appears to be a safe, effective and innovative technique to manage a single large HCC.
机译：评估三维（3D）可视化平台辅助的超声引导经皮微波消融术（US-PMWA）的临床疗效和可行性，该平台用于治疗单个大肝细胞癌（HCC）（直径≥5？cm）。从2015年5月至2017年8月，我们纳入了40名患有单个大肝癌的患者。19名在3D可视化平台的协助下接受US-PMWA的患者组成3D组;没有3D可视化协助的21名患者组成了对照组。使用3D可视化治疗平台成功进行了术前计划和术后评估。比较两组之间的热消融参数，生存率和复发率。 3D组的主要疗效率和无复发生存率（RFS）高于对照组（分别为p？= ?. 007和p？= ?. 014）。 3D组中插入的探针数量高于对照组中的探针数量（p≥＝ .016）。 3D组的总生存（OS）率与对照组相当（p？= ?. 745）。估计3D组的3年OS和RFS发生率分别为38.5％和64.6％，对照组为34.4％和18.8％。使用肿瘤图评估治疗效果，并通过传统的对比增强超声在3D组中进行确认。首次治疗后，有9名患者（47.4％）完全消融，安全裕度为5毫米。没有发生与消融有关的主要并发症。 US-PMWA在3D可视化治疗平台的协助下可以提高治疗效率，并且似乎是管理单个大型HCC的安全，有效和创新的技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号